KEY POINTS
- SRAM (NCT03938649) is a single-center randomized, open-label phase II trial from The Chinese University of Hong Kong, comparing once-weekly pelvis-inclusive SBRT with conventionally fractionated IMRT in node-negative high-risk prostate cancer. Between September 2019 and April 2024, 126 men were randomized and 121 were evaluable, including 60 in the SBRT group and 61 in the IMRT group. All received androgen deprivation therapy starting before irradiation and continuing for 18–24 months.
- The SBRT regimen delivered 40 Gy to the prostate, 36.25 Gy to the proximal seminal vesicles, and 25 Gy to elective pelvic nodes in five once-weekly fractions. Conventional IMRT delivered 50 Gy in 25 fractions to the prostate and pelvis, followed by a 26-Gy prostate boost in 13 fractions, totaling 76 Gy. Both approaches used VMAT, daily CBCT, and fiducial-guided positioning, with prostate PTV margins of 5 mm/3 mm posterior for SBRT versus 10 mm/6 mm posterior for IMRT. Rectal spacers were not used.
- Physician-graded gastrointestinal toxicity was not significantly different between groups at 6–12 months. Grade ≥2 GI toxicity occurred in 16.7% with SBRT versus 13.1% with IMRT (p=0.583), while grade ≥2 GU toxicity occurred in 11.7% versus 16.4% (p=0.455). Rectal hemorrhage was the most frequent moderate GI event, occurring in 13.3% versus 6.6%. One patient in the SBRT group developed grade 3 rectal hemorrhage, with no grade ≥3 GU events in either group.
- Patient-reported bowel quality of life was significantly worse after SBRT. Mean EPIC bowel scores were 83.2 versus 92.4 at nine months (p=0.0022) and 82.5 versus 90.1 at 12 months (p=0.0181) for SBRT versus IMRT. At 12 months, the mean change from baseline was −13.9 points with SBRT versus −5.4 with IMRT (p=0.0123). The deterioration after SBRT exceeded the study's predefined 10-point threshold for clinically meaningful bowel-domain change.
- Urinary patient-reported outcomes remained broadly similar. At 12 months, mean EPIC urinary-domain scores were 77.5 after SBRT versus 79.2 after IMRT (p=0.590). Mean IPSS scores were 14.48 versus 14.03, without a significant difference, and urinary function, incontinence, and irritative symptom subdomains were also comparable. Grade ≥1 GU toxicity was less frequent after SBRT (78.3% vs 98.4%; p=0.0004), despite similar moderate GU toxicity.
- Planning-dose characteristics provide a possible explanation for the bowel-function signal. The authors note that SBRT rectal planning constraints corresponded to high biologically equivalent doses, including approximately 94.2 Gy EQD2 for maximum point dose and 80.6 Gy EQD2 for D3cc using α/β = 3 Gy. However, these were protocol constraints rather than measured patient-specific delivered doses, so the relationship between rectal dose hotspots and later bowel symptoms was not directly tested.
- The analysis was not powered to establish long-term toxicity equivalence. The parent trial's primary endpoint was acute grade ≥2 toxicity, whereas the current analysis reports secondary toxicity and quality-of-life outcomes through 12 months. Mean follow-up exceeded four years, but the presented longitudinal EPIC data stopped at one year, and 24-month assessments remained immature. Additional limitations include a single experienced center, absent rectal spacers, no patient-level dosimetric correlation, and no multiplicity adjustment for exploratory patient-reported endpoints.
CLINICAL TAKEAWAY
Once-weekly pelvic SBRT did not significantly increase physician-graded moderate GI or GU toxicity compared with conventional IMRT, but patients reported clinically meaningful worsening of bowel quality of life at nine and 12 months. These randomized phase II findings highlight the importance of patient-reported outcomes when evaluating ultrahypofractionated elective pelvic irradiation. Longer follow-up and refined rectal dose constraints are needed before routine pelvis-inclusive SBRT can be considered equivalent in tolerability to conventional treatment.